Business Context and Reporting Period
Spyre Therapeutics, Inc. (SYRE) filed a Form 8-K on February 19, 2026, to announce financial results for the fourth quarter and fiscal year ended December 31, 2025. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not provide data to compare current period results against prior comparable periods. No specific material changes in financial condition or operations are detailed in the excerpt.
Guidance, Outlook, and Risks
The filing references a press release containing the results but does not include specific management commentary, forward-looking guidance, risk factors, or unusual items within the provided text. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2025 financial figures.
- Verify cash runway and burn rate details not present in the 8-K summary.
- Confirm any updates to clinical trial timelines or regulatory milestones mentioned in the full press release.
- Check for any new debt covenants or liquidity events disclosed in the full exhibit.